|
WuXi Pharmatech and OMT expand antibodies agreement
PMLiVE Chinese contract research organisation (CRO) WuXi Pharmatech and US therapeutic antibodies developer Open Monoclonal Technology (OMT) have agreed to expand WuXi’s use of OMT’s antibodies technology across Asia. The agreement enables WuXi to … |
Knee Rheumatoid ArthritisNews-Medical.netA newer approach is to use biological agents. TNF inhibitors were the first licensed biological agents including etanercept, infliximab, adalimumab and certolizumab. This was followed by monoclonal antibodies li…
MedscapeCost Restricts RA Drug Access in EuropeMedscapeThe bDMARDs surveyed included infliximab, etanercept, adalimumab, certolizumab pegol, golimumab, abatacept, tocilizumab, and rituximab. The cost of annual treatment with sDMARDs never exceeded GDP,…
Scientists Study How Immune Cells are Able to Advance Their Own EvolutionInfection Control TodayAntibodies and immune cells are marked with different colors. Image by University of Birmingham/Toellner. Immune system B cells play a crucial role in the d…
SymBio Pharma completes patient enrollment in phase II trial of Treakisym in …pharmabiz.comCurrently, R-CHOP is prescribed as a standard therapy, however, clinical trial results in the U.S. and Europe have shown superiority of the combination of ritu…
|
Emergent’s CEO Discusses Q4 2012 Results – Earnings Call Transcript
Seeking Alpha In 2012, they initiated two exciting chemical trials for TRU-016 a Phase 1b study that combined TRU-016 with Rituximab in frontline CLL and a Phase 2 study that combines TRU with bendamustine in relapsed refractory CLL. We are very excited about the … |
|
Biogen Idec (NASDAQ: BIIB) wird auf der 65.
Ad-Hoc-News (Pressemitteilung) Das Unternehmen wird außerdem Ergebnisse aus den Forschungsstudien zu seinen in der späten Entwicklungsphase befindlichen MS-Arzneimittelkandidaten vorlegen, darunter TECFIDERA™ (Dimethylfumarat), Peginterferon beta-1a und Daclizumab … |
|
BUSINESS WIRE: Biogen Idec stellt neue Ergebnisse zu vielfältigem …
Vereinigte Wirtschaftsdienste Das Unternehmen wird außerdem Ergebnisse aus den Forschungsstudien zu seinen in der späten Entwicklungsphase befindlichen MS-Arzneimittelkandidaten vorlegen, darunter TECFIDERATM (Dimethylfumarat), Peginterferon beta-1a und Daclizumab … |
|
Biogen Idec stellt neue Ergebnisse zu vielfältigem neurologischen Portfolio …
finanzen.ch Das Unternehmen wird ausserdem Ergebnisse aus den Forschungsstudien zu seinen in der späten Entwicklungsphase befindlichen MS-Arzneimittelkandidaten vorlegen, darunter TECFIDERA™ (Dimethylfumarat), Peginterferon beta-1a und Daclizumab … |
|
Biogen Idec presenterà i nuovi dati relativi al suo portafoglio di prodotti …
informazione.it (Comunicati Stampa) … rilascio prolungato di fampridina). L’azienda presenterà anche i risultati degli studi sperimentali della sua pipeline avanzata per la SM, fra cui TECFIDERA™ (dimetilfumarato), peginterferone beta-1a e il processo ad alto rendimento Daclizumab … |